 |
|
|
| |
GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With
Low-Dose Ribavirin QD in Patients With Genotype 1a Chronic Hepatitis C Virus Infection Without Cirrhosis
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Fred Poordad1, Shahriar Sedghi2, Paul J Pockros3, Natarajan Ravendhran4, Robert Reindollar5, Michael R Lucey6, Michael Epstein7, Leslie Bank8, David Bernstein9, Roger Trinh10,
Preethi Krishnan10, Tami Pilot-Matias10, Akshanth R Polepally10, Rajvineeth Kumar Pothacamury10, Kristina Unnebrink11, Marisol Marti nez10, David R Nelson12
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, United States; 2Associate Professor of Medicine and Surgery, Mercer University School of Medicine, Macon, Georgia, United States; 3Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, California, United States; 4Digesti ve Disease Associates, Baltimore, Maryland, United States; 5Piedmont Healthcare/Carolinas Center for Liver Disease, Statesville, North Carolina, United States; 6Division of Gastroenterology/Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States; 7Anne Arundel Medical Center, Digestive Disorders Associates, Annapolis, Maryland, United States; 8Principal Investigator, Regional Clinical Research Inc., Endwell, New York, United States; 9Hofstra Northwell School of Medicine, Manhasset, New York, United States;
10AbbVie Inc., North Chicago, Illinois, United States; 11AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany; 12Department of Medicine, University of Florida, Gainesville, Florida, United States
|
| |
|
|
|
|
|
